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Conclusion: RT remains an important modality in the treatment of 
NHL.  
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Background: Cure rates of patients with lymphoma have improved 
significantly over the last decades because of improved diagnostics, 
chemo(immuno)therapy and radiotherapy. There is, however, a large 
variety of late effects following treatment for lymphoma including 
decreased fertility, hormonal disturbances, pulmonary toxicity, soft 
tissue damage, second malignancies and cardiovascular diseases 
leading to considerable morbidity and excess mortality. The long-term 
burden of lymphoma treatment is determined by a combination of all 
late effects. Since (non) Hodgkin lymphoma ((N)HL) frequently occurs 
at relatively young ages, survivors are subject to the full spectrum of 
early and late side effects of therapy. Over time knowledge and 
awareness of late effects following cancer treatment have increased 
and treatment policies have been adapted accordingly. 
Improvement of treatment: Several randomized clinical trials have 
been performed to determine the role of radiation in lymphoma 
patientsespecially in HL patients. Radiation indication, target volume 
and dose have been subject of study. Since many important long-term 
complications (like second malignancies and cardiovascular toxicity) 
are related to radiation dose and volume, reduction of these 
treatment parameters are expected to ameliorate long-term toxicity 
(1,2). 
Reducing volume 
Over the last decades radiation volumes in lymphoma patients have 
changed considerably because of better knowledge in the spread of 
the disease through improved diagnostic possibilities and improved 
systemic treatments. 
In HL patients for instance radiation field-sizes have been reduced 
from subtotal-nodal or extended field to involved field or, more 
recently, involved site or involved node leading to smaller volumes of 
normal tissues exposed to significantly lower radiation doses. A word 
of caution, however: involved node radiotherapy should not be 
applied strictly when optimal pre-chemotherapy imaging is not 
available to the radiation oncologist. In this situation more generous 
margins should be used including the whole “site” where the 
lymphoma was located before chemotherapy. 
Furthermore, in early stage gastric lymphoma patients, total 
abdominal irradiation has been replaced by radiotherapy limited to 
the stomach and the surrounding lymph nodes using modern radiation 
techniques in selected patients only.  
Reducing dose 
For both HL and many subtypes of NHL systemic treatment options 
have improved significantly. These improvements have led to the 
possibility to reduce both radiation dose and volume while 
maintaining similar treatment outcomes (3). In the past generally 
doses up to 40-45 Gy in fractions of 2 Gy were used. Nowadays 
radiation doses in curative setting usually vary from 20 to 30 Gy and 
sometimes 36 Gy in fractions of 2 Gy. 
Technical improvements 
Deep inspiration breath hold 
In selected patients withmediastinal disease the use of deep 
inspiration breath hold and intensity modulated radiation therapy is 
expected to decrease exposure of the coronary arteries, heart, and 
lungs especially when the target volume is located in the upper part 
of the mediastinum (4).  
Proton therapy 
Another emerging technology is proton therapy. Proton therapy is 
associated with a substantial reduction in radiation dose to critical 
organs, such as the heart and lungs, and therefore has the potential to 
improve not only the therapeutic ratio, but also both event-free and 
overall survival.  
Conclusions 
Patient tailored radiotherapy inlymphoma patients using lower doses, 
smaller and better-defined radiation volumes than in the past, based 
on modern imaging and using conformal radiotherapy are expected to 
lead to an improved therapeutic ratio and decreased late effects. 
Further improvements are expected with the introduction of even 
more modern radiation techniques like deep inspirational breath hold. 
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 SYMPOSIUM: MICROENVIRONMENT  
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Hypoxia is a cancer hallmark impacting tumor progression and 
treatment. From a biological standpoint, it promotes (i) a glycolytic 
switch formally corresponding to uncoupling glycolysis from oxidative 
phosphorylation and accelerating the glycolytic flux in order to fulfill 
the energetic and biosynthetic needs of cancer cells, (ii) an 
angiogenic switch, and (iii) a metastatic switch. From a therapeutic 
standpoint, hypoxia provides radioresistance notably because oxygen 
is molecularly involved in the stabilization of radiation-induced DNA 
damage. Among several interventions intended to improve oxygen 
availability to radiosensitize tumors, mathematical models indicate 
that those targeting tumor cell metabolism would be particularly 
efficient. Indeed, even a moderate inhibition of tumor cell respiration 
is predicted to significantly increase tumor oxygenation. 
Switching to a glycolytic metabolism is associated with the abundant 
release of lactate, the level of which positively correlates with tumor 
aggressiveness in patients. Although it was often considered as a mere 
glycolytic end-product, our work over the last 5 years showed that 
lactate is a direct tumor growth-promoting factor influencing tumor 
metabolism and angiogenesis. We first evidenced that lactate is a 
metabolic substrate preferred to glucose to fuel the oxidative 
activities of oxygenated tumor cells. This metabolic preference 
supports a metabolic symbiosis in which (i) hypoxic/glycolytic tumor 
cells produce lactate, (ii) oxygenated/oxidative tumor cells consume 
lactate sparing glucose, and (iii), consequently, glucose is made 
optimally available to fuel accelerated glycolysis in the hypoxic tumor 
cell compartment. Tumor-associated fibroblasts may constitute an 
additional source of lactate. We next found that lactate is also a 
signaling agent promoting tumor angiogenesis. Lactate oxidation to 
pyruvate, the LDH reaction, is shared by both metabolic and signaling 
paths. However, although pyruvate can be consumed in the 
mitochondrion to sustain oxidative ATP production, it can also 
competitively inhibit HIF-1 prolylhydroxylases even under normoxia. 
Lactate thereby activates the transcription factors HIF-1 in 
oxygenated tumor and endothelial cells and NF-κB in endothelial cells, 
thus triggering pro-angiogenic VEGF, bFGF and IL-8 signaling. We 
finally found that the metabolic and signaling use of lactate requires 
monocarboxylate transporter 1 (MCT1), a passive lactate-proton 
symporter located at the outer membrane of oxygenated tumor and 
endothelial cells where it facilitates lactate uptake. Targeting MCT1 
pharmacologically or with RNA interference first induced a glycolytic 
switch and, therefore, oxygen sparing in the oxygenated tumor cell 
compartment. It consequently eradicated the hypoxic tumor cell 
compartment by virtue of glucose starvation, whereas the remaining 
MCT1-positive tumor cells could be efficiently treated with X-ray 
radiotherapy as they were fully reoxygenated. MCT1 inhibition also 
blocked lactate signaling and tumor angiogenesis. 
Conclusively, our study shows (i) that lactate is a pleiotropic tumor 
growth-promoting factor, and (ii) that MCT1 inhibitors combine 
antimetabolic, radiosensitizing, and anti-angiogenic antitumor effects 
within a same molecule. A first MCT1 inhibitor, AZD-3965, is currently 
entering into clinical trials in UK. 
   
SP-0642   
Extracellular matrix: What is it good for? Absolutely everything 
N. Cordes1 
1OncoRay - Center for Radiation Research in Oncology, TU Dresden, 
Dresden, Germany  
 
Tumors similar to normal tissues contain extracellular matrix (ECM). 
Through integrin cell surface receptor binding, cells are integrated 
into multicellular structures and eventually tissues and organs. 
Different from normal tissues are the amount and organization of ECM 
in tumors giving rise to increased intratumoral pressure, tumor cell 
invasion, cancer stem cell niche development,and therapy resistance. 
Our understanding of adhesion-mediated tumor cell radio- and 
chemoresistance are still in its infancy. Evidently, integrin signaling 
activates key pro-survival determinants such as focal adhesion kinase, 
Akt, MAPK among many others, while the structural integrin-mediated 
cell-actin connection controls cell morphology including nuclear 
matrix and chromatin organization. Studies in normal cells such as 
fibroblasts or endothelial cells have revealed that all known cell 
functions ranging from cell survival to metabolism are co-regulated by 
